Slide 1: Exchange filing cover letter: Presentation for Analyst / Institutional Investor Meetings
13rd February 2024 (1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Bandra Kurla Complex, Mumbai 400 001 Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Sc
Slide 2: Nuvama India Conference 2024
Nuvama India Conference 2024 Ashish Adukia - Global Chief Financial Officer Jasdeep Singh - Global Chief Strategy Officer
Slide 3: Disclaimer
DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 4: Agenda
Agenda Journey India Cipla Way So Far Trends Forward 3
Slide 5: Cipla Journey So Far
Cipla Journey So Far
Slide 6: Established in 1935: Grown into one of the most respected companies globally
Established in 1935: Grown into one of the most respected companies globally 85+ $3 Bn 24%+ Markets Revenues EBITDA 47 50+ 26,000+ State of art Dosage Employees manufacturing forms facilities Note: Revenue and EBITDA of last 4 qtrs (Q4’ FY23 – Q3’ FY24) 5
Slide 7: Performance for purpose
Performance for purpose Strong execution to establish market leadership, build differentiated pipeline and accelerate our journey to being a global healthcare company Revenue from (₹ in crores) EBITDA and EBITDA (₹ in crores) Return on Invested (in %) Operations Margin1 Capital (RoIC)3 Dividend payo
Slide 8: Global footprint with strong portfolio and execution capabilities across its key markets
Global footprint with India strong portfolio and 3rd largest in the India domestic Rx market; Leadership in Gx 1st rank in Respiratory; top 5 in Urology and Anti-infectives execution capabilities 7,500+ field force detailing to HCPs across the country – 85% physicians prescribe at-least one Cipla pr
Slide 9: Leverage innovation for growth
Leverage innovation for growth 1650 scientists|5 R&D facilities|303 patents granted till date Investment in niche/complex opportunities in the U.S. New Products Launched 55+ New Product launches since 2017 81 93 78 Cumulative sales from $ Mn IQVIA Sales 826 New Launches FY 2020-21 FY 2021-22 FY 2022
Slide 10: Cipla stays anchored to its motto – "None shall be denied"
Cipla stays anchored to its motto – “None shall be denied” Strong R&D leveraged to develop solutions that address unmet medical needs, improve access to life-saving medicines Cipla continues to innovate in HIV Then: Offered ARV triple combo Now: Worked with DNDi for Quadrimune During the AIDS crisis
Slide 11: Cipla remained at the forefront of Covid care, displaying unwavering resilience
Cipla remained at the forefront of Covid care, displaying unwavering resilience Cipla accelerated ‘Access to life-saving drugs’ for Covid and launched multiple products RT-PCR testing and Antibody Cocktail Antivirals Immunosuppressants Antigen testing Kits Served 1.2 Lacs patients Set-up Covid helpl
Slide 12: India Trends
Cipla India Trends
Slide 13: Patient Pool: Growth of ~20% expected between 2021 and 2030
Patient Pool: Growth of ~20% expected between 2021 and 2030 Reducing fertility rates, ageing population, increasing chronic ailments and better awareness among patients are resulting in higher patient pool Evolving Demographics India ageing, elderly to make up 20% of population by 2050 increasing th
Slide 14: Trends in Surgery
Trends in Surgery | Advanced technologies driving adoption of both High- end complex and minimally invasive surgeries Hi-Tech complex surgeries Minimally Invasive Procedures Estimated increase of over 30% in the past five years in major Such as Bi-valve replacement, Ortho surgery etc metro cities. J
Slide 15: Surge in Preventive Care
Surge in Preventive Care | With Curative Healthcare remaining heavily strained, focus has been shifting to Preventive Healthcare Indian Healthcare Spend in $ Bn (Private + Government) Over 60% now prioritize regular health check- Curative Preventive ups a significant increase from a decade ago ~487
Slide 16: Trends in Diagnostics
Trends in Diagnostics | Accurate, accessible, and personalized diagnosis to expand patient pool and improve clinical outcomes Advanced Imaging Point-of-Care Genomic Technologies (AIT) Testing (POCT) Testing (GT) Expected to grow at a CAGR of Valued at $9.54 Bn in 2022 and is The market for POCT in I
Slide 17: Town 2-6 towns expected to account for incremental healthcare growth
Town 2-6 towns Government initiatives and support Rising healthcare awareness and demand expected to account Policies and schemes Increased health awareness for incremental Ayushman Bharat PM-JAY aim to provide Facilitated by digital penetration. This health insurance to 50cr beneficiaries awareness
Slide 18: Channel play should be designed to accommodate both organized & unorganized retail
Channel play should be designed to accommodate both organized & unorganized retail Organized players expected to garner a market share of 20-25% by 2027 ~80% chemists still will be a part of unorganized retail Unorganized Retail Organized Retail 9-10% p.a. CAGR, 41 FY22-27 26 20-25% 15 25-30% 9-11%
Slide 19: Generative AI: A once-in-a-generation technology surges into healthcare industry
Enhanced efficiency and productivity Generative AI: Outpatient journeys and clinical documentation for improved patient care. Shortage of both clinical and non-clinical talent (e.g., only 64 doctors per A once-in-a-generation 100,000 patients compared to the global average of 150 per 100,000) techno
Slide 20: Cipla Way Forward
Cipla Cipla Way Forward
Slide 21: Cipla is making strategic moves to offer "Beyond the Pill"
Cipla is making strategic moves to offer “Beyond the Pill” Growth Passion Innovation Pioneering Championing Engine care 20
Slide 22: Future Fit Cipla: Aspiration to build bolder presence across key markets
Future Fit Cipla: Aspiration to build bolder presence across key markets Growth Passion Innovation Pioneering Championing Engine care ONE SOUTH NORTH INTERNATIONAL INDIA AFRICA AMERICA MARKETS To be 2 nd 2nd 2x To be Largest To be To Largest Largest Gx by revenue Pharma Pharma company in respiratory
Slide 23: Future Fit Cipla: Redefining Respiratory – Bridging the ecosystem from Illness to Wellness
Future Fit Cipla: Redefining Respiratory – Bridging the ecosystem from Illness to Wellness Growth Passion Innovation Pioneering Championing Engine care Breathefree – Scaling & launching commercial modules Diagnosis Awareness and Adoption 6,42,000+ App Downloads Launched Spirofy and working on Spiro
Slide 24: Future Fit Cipla: Stay relevant, Build "Beyond the Pill"
Future Fit Cipla: Stay relevant , Build “Beyond the Pill” Growth Passion Innovation Pioneering Championing Engine care Investing in complex, differentiated, new-age platforms Oligonucleotides Cell & Gene therapy mRNAs (Genomics) Specialty Stem cells Respiratory Peptides therapies Complex Nebulizatio
Slide 25: Future Fit Cipla: To lead, grow into an integrated healthcare player
Future Fit Cipla: To lead, grow into an integrated healthcare player Growth Passion Innovation Pioneering Championing Engine care High engagement with Start-up ecosystem via Entering POC model by Leveraging Cipla’s reach with VC Investments doctors, clinics, nursing homes Oncology Cippoint Mental He
Slide 26: Future Fit Cipla: Sustainability Champion
Future Fit Cipla: Sustainability Champion Growth Passion Innovation Pioneering Championing Engine care Culture CARING FOR PEOPLE, Great places to work certified and strive to be in the top 100 companies across industries PLANET AND PURPOSE Build a culture of inclusion – Enhancing diversity across de
Slide 27: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Ajinkya Pandharkar Investor.Relations@cipla.com Diksha Maheshwari Investor.Relations@cipla.com For more information please visit www.ci